COVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.
If you are not happy with the results below please do another search
50 search results for:
The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna Covid-19 vaccines, top U.S. infectious disease official Anthony Fauci told the Washington Post newspaper.
The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer,” should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said.
U.S. vaccine developer Inovio Pharmaceuticals completed Phase II enrollment for a mid-to-late stage U.S. trial of the company’s Covid-19 vaccine candidate and expects to report data early in the second quarter.
The United States reported a 3 percent decline in new cases of Covid-19 for the week ended Feb. 28, a much smaller drop than in the previous six weeks, and health officials warned that progress against the global pandemic was stalling.
The number of new coronavirus infections globally rose for the first time in seven weeks, the World Health Organization said on March 1.
Merck announced on March 1 the voluntary withdrawal of the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Reuters reported that AstraZeneca sold off the U.K. pharma giant’s 7.7 percent stake in the Covid-19 vaccine manufacturer Moderna for more than $1 billion.
The U.S. Food and Drug Administration approved BridgeBio Pharma and affiliate Origin Biosciences’ injectable, rare genetic metabolic disorder therapy Nulibry (fosdenopterin).
Darmstadt, Germany-based Merck KGaA plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.